Immunotherapy in hepatocellular carcinoma: Primed to make a difference?
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Advanced hepatocellular carcinoma (HCC) carries a dismal prognosis and the current treatment is limited to sorafenib, an agent with modest benefit. Preclinical data have indicated that several immunologic mechanisms are at play to promote HCC development and growth while impairing effective antitumor immune surveillance. Several novel approaches geared toward manipulating the immune response to HCC have suggested a therapeutic benefit in early‐stage clinical trials, indicating a real potential to augment tumor‐specific immunity and improve outcomes in patients with this disease. In the current study, the authors reviewed the barriers to an effective immune response against HCC and contemporary clinical investigations that may be “primed” to alter the natural history of HCC. Cancer 2016;122:367–377. © 2015 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Noman, M. Z., Desantis, G., Janji, B., Hasmim, M., Karray, S., Dessen, P., Bronte, V., & Chouaib, S. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20131916 · Cited by 2,166 · cited 2×
“L1 expression is protean, increasing with modalities that induce hypoxia (ie, embolization or sorafenib).(111,114)”
BackgroundMethodSchulze, K., Imbeaud, S., Letouzé, E., Alexandrov, L. B., Calderaro, J., Rebouissou, S., Couchy, G., Meiller, C., Shinde, J., Soysouvanh, F., et al. (2015) · Nature Genetics · doi:10.1038/ng.3252 · Cited by 1,803
A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells
Carreno, B. M., Magrini, V., Becker-Hapak, M., Kaabinejadian, S., Hundal, J., Petti, A. A., Ly, A., Lie, W.-R., Hildebrand, W. H., Mardis, E. R., et al. (2015) · Science · doi:10.1126/science.aaa3828 · Cited by 1,285
Immune surveillance by the liver
Jenne, C. N., & Kubes, P. (2013) · Nature Immunology · doi:10.1038/ni.2691 · Cited by 1,047
Hoechst, B., Ormandy, L. A., Ballmaier, M., Lehner, F., Krüger, C., Manns, M. P., Greten, T. F., & Korangy, F. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.020 · Cited by 793
Limmer, A., Ohl, J., Kurts, C., Ljunggren, H.-G., Reiss, Y., Groettrup, M., Momburg, F., Arnold, B., & Knolle, P. A. (2000) · Nature Medicine · doi:10.1038/82161 · Cited by 758 · cited 1×
“Liver sinusoidal endothelial cells (LSECs), the fenestrated cellular barrier between the sinusoidal blood and hepatocytes, have antigen-presenting cell (APC) function, expressing toll-like receptors and the major histocompatibility complex (MHC) class I and II molecules.(5) It is interesting to note that LSECs express…”
BackgroundLi, H., Wu, K., Tao, K., Chen, L., Zheng, Q., Lu, X., Liu, J., Shi, L., Liu, C., Wang, G., et al. (2012) · Hepatology · doi:10.1002/hep.25777 · Cited by 496
Chen, Y., Ramjiawan, R. R., Reiberger, T., Ng, M. R., Hato, T., Huang, Y., Ochiai, H., Kitahara, S., Unan, E. C., Reddy, T. P., et al. (2015) · Hepatology · doi:10.1002/hep.27665 · Cited by 451
Nakamoto, N., Cho, H., Shaked, A., Olthoff, K., Valiga, M. E., Kaminski, M., Gostick, E., Price, D. A., Freeman, G. J., Wherry, E. J., et al. (2009) · PLoS Pathogens · doi:10.1371/journal.ppat.1000313 · Cited by 380
Wu, K., Kryczek, I., Chen, L., Zou, W., & Welling, T. H. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0901 · Cited by 380
Cited by
The immunology of hepatocellular carcinoma
Ringelhan, M., Pfister, D., O’Connor, T., Pikarsky, E., & Heikenwalder, M. (2018) · Nature Immunology · doi:10.1038/s41590-018-0044-z · Cited by 1,076
Hendry, S., Salgado, R., Gevaert, T., Russell, P. A., John, T., Thapa, B., Christie, M., van de Vijver, K., Estrada, M. V., Gonzalez-Ericsson, P. I., et al. (2017) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000161 · Cited by 799
The Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma: A Review
Pinter, M., Jain, R. K., & Duda, D. G. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2020.3381 · Cited by 339
Zhao, Y., Shuen, T. W. H., Toh, T. B., Chan, X. Y., Liu, M., Tan, S. Y., Fan, Y., Yang, H., Lyer, S. G., Bonney, G. K., et al. (2018) · Gut · doi:10.1136/gutjnl-2017-315201 · Cited by 200
Hepatic Stellate Cell-Macrophage Crosstalk in Liver Fibrosis and Carcinogenesis
Matsuda, M., & Seki, E. (2020) · Seminars in Liver Disease · doi:10.1055/s-0040-1708876 · Cited by 189
Metadata
- Authors
- Harding, J. J., El Dika, I., & Abou‐Alfa, G. K.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2015-11-05
- Volume
- 122
- Issue
- 3
- Pages
- 367-377
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2127884599
- Cited by
- 124
- References
- 13
- FWCI
- 9.04
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Immunotherapy in hepatocellular carcinoma: Primed to make a difference? https://app.cochat.ai/papers/10.1002/cncr.29769
- The paper
- Harding, J. J., El Dika, I., & Abou‐Alfa, G. K. (2016). Immunotherapy in hepatocellular carcinoma: Primed to make a difference? Cancer. https://doi.org/10.1002/cncr.29769
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.